Literature DB >> 20031162

Cancer therapy beyond apoptosis: autophagy and anoikis as mechanisms of cell death.

Jodi M Coates1, Joseph M Galante, Richard J Bold.   

Abstract

Apoptosis has long been recognized as a critical mechanism of programmed cell death that is preserved among all eukaryotes and is involved in a variety of disease processes. Malignant transformation of cells is associated with a constellation of pro-survival mutations rendering them resistant to apoptosis. Traditional cancer therapy evokes cell death by inducing apoptosis; however, the apoptotic resistance inherent in cancer cells has been a significant barrier to effective chemotherapy. More recently, other mechanisms of cell death have emerged as potential novel mechanisms for cancer therapies to induce cell death, either in addition to, or instead of, apoptosis-induced cytotoxic treatment. Autophagy is a process that occurs in all cells, but is induced in many types of cancer. Autophagy functions as both a cell survival and a cell death mechanism depending on the context and the stimuli, which are likely exploitable for cancer therapy. Anoikis is also a physiologic process in normal cells used to maintain homeostasis, in which cell death is induced in response to loss of extracellular membrane (ECM) attachment. Cancer cells are notoriously resistant to anoikis, enabling metastasis and new tumor growth beyond their original environment. Interestingly, autophagy may actually by a major contributor to anoikis resistance in cancer. As these two processes are elucidated in more detail, there is great potential for novel targets that affect cancer cell death, in addition to the current cytotoxic agents.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20031162     DOI: 10.1016/j.jss.2009.07.011

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  20 in total

1.  Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo.

Authors:  Prabodh K Kandala; Sanjay K Srivastava
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

Review 2.  Significance of talin in cancer progression and metastasis.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

Review 3.  Autophagy as a pro-death pathway.

Authors:  Donna Denton; Tianqi Xu; Sharad Kumar
Journal:  Immunol Cell Biol       Date:  2014-10-21       Impact factor: 5.126

4.  Decreased expression of Beclin-1 and LC3 in human lung cancer.

Authors:  Zi-Feng Jiang; Li-Jie Shao; Wei-Min Wang; Xue-Bo Yan; Rong-Yu Liu
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

Review 5.  SIRT3 and cancer: tumor promoter or suppressor?

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Eric Verdin; Yvonne L Kapila
Journal:  Biochim Biophys Acta       Date:  2011-05-07

6.  STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells.

Authors:  Neel M Fofaria; Sanjay K Srivastava
Journal:  Carcinogenesis       Date:  2014-11-19       Impact factor: 4.944

Review 7.  The potential roles and mechanisms of non-coding RNAs in cancer anoikis resistance.

Authors:  Tongguo Shi; Chuanqiang Zhang; Suhua Xia
Journal:  Mol Cell Biochem       Date:  2022-02-10       Impact factor: 3.396

Review 8.  Potential roles of longan flower and seed extracts for anti-cancer.

Authors:  Chih-Cheng Lin; Yuan-Chiang Chung; Chih-Ping Hsu
Journal:  World J Exp Med       Date:  2012-08-20

Review 9.  Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis.

Authors:  Kevin Tan; David Goldstein; Philip Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-04       Impact factor: 4.553

10.  A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

Authors:  David S Hong; Jennifer Hsing Choe; Aung Naing; Jennifer J Wheler; Gerald S Falchook; Sarina Piha-Paul; Stacy L Moulder; Goldy C George; Jonathan M Choe; Lewis C Strauss; Gary E Gallick; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2012-11-20       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.